- Home
- UTSI vs CRIS Comparison
UTSI vs CRIS Comparison
Compare UTSI & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTSI
- CRIS
- Stock Information
- Founded
- UTSI 1991
- CRIS 2000
- Country
- UTSI China
- CRIS United States
- Employees
- UTSI N/A
- CRIS N/A
- Industry
- UTSI Telecommunications Equipment
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UTSI Telecommunications
- CRIS Health Care
- Exchange
- UTSI Nasdaq
- CRIS Nasdaq
- Market Cap
- UTSI 24.9M
- CRIS 21.3M
- IPO Year
- UTSI 2000
- CRIS 2000
- Fundamental
- Price
- UTSI $2.67
- CRIS $1.80
- Analyst Decision
- UTSI
- CRIS Strong Buy
- Analyst Count
- UTSI 0
- CRIS 2
- Target Price
- UTSI N/A
- CRIS $16.50
- AVG Volume (30 Days)
- UTSI 5.9K
- CRIS 179.9K
- Earning Date
- UTSI 09-04-2025
- CRIS 07-31-2025
- Dividend Yield
- UTSI N/A
- CRIS N/A
- EPS Growth
- UTSI N/A
- CRIS N/A
- EPS
- UTSI N/A
- CRIS N/A
- Revenue
- UTSI $10,878,000.00
- CRIS $11,202,000.00
- Revenue This Year
- UTSI N/A
- CRIS N/A
- Revenue Next Year
- UTSI N/A
- CRIS $10.67
- P/E Ratio
- UTSI N/A
- CRIS N/A
- Revenue Growth
- UTSI N/A
- CRIS 14.17
- 52 Week Low
- UTSI $1.84
- CRIS $1.02
- 52 Week High
- UTSI $3.22
- CRIS $8.29
- Technical
- Relative Strength Index (RSI)
- UTSI 57.72
- CRIS 42.69
- Support Level
- UTSI $2.65
- CRIS $1.70
- Resistance Level
- UTSI $2.79
- CRIS $2.01
- Average True Range (ATR)
- UTSI 0.16
- CRIS 0.21
- MACD
- UTSI 0.02
- CRIS -0.03
- Stochastic Oscillator
- UTSI 57.27
- CRIS 38.78
About UTSI UTStarcom Holdings Corp.
UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.